Study on rAd5F35-SIVenvT vaccine in combination with rMVA-SIVenvT vaccine in mice
10.3760/cma.j.cn112309-20201222-00560
- VernacularTitle:重组嵌合腺病毒35型和重组痘苗病毒SIV疫苗在小鼠体内联合免疫的实验研究
- Author:
Xiaozhou HE
1
;
Jing YANG
;
Hongxia LI
;
Yanzhe HAO
;
Xia FENG
Author Information
1. 中国疾病预防控制中心病毒病预防控制所，北京 102206
- Keywords:
rAd5F35;
rMVA;
Cellular immunology;
Humoral immunity;
Simian immunodeficiency virus
- From:
Chinese Journal of Microbiology and Immunology
2021;41(6):455-459
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To analyze the immune response in mice after immunization with vaccine of rAd5F35-SIVenvT in combination with rMVA-SIVenvT to evaluate the efficacy of different immunization strategies.Methods:Two recombinant viruses were identified in vitro by PCR and Western blot. The BALB/c mice were immunized with homologous and heterologous immune strategies. The numbers of splenic lymphocytes secreting IFN-γ were measured by ELISPOT assay, meanwhile SIV gp120 antibody titer were measured by ELISA assay. Results:SIVenvT protein was expressed effectively by rAd5F35-SIVenvT and rMVA-SIVenvT in HEK293 cells. The specific immune response reached its peak at 4-week post first immunization, then decreased. SIV Env specific cellular immune response and SIV gp120 specific antibody could be detected at 4-16 weeks post first immunization. The specific cellular response was significant stronger in heterologous immunization group than homologous group at 4 week and 16 week. Furthermore, heterologous immunization induced significant higher titer of SIV gp120 antibody at 4 week than homologous group.Conclusions:Specific immune response induced by rAd5F35-SIVenvT in combination with rMVA-SIVenvT was stronger than homologous vector immunization. The results provided references for further study in nonhuman primates.
